[
  {
    "clause_index": 4,
    "start_char": 1687,
    "end_char": 2265,
    "original": "Based on the foregoing, and subject to the terms and conditions contained in this Agreement, the Agents severally and not jointly agree to act as, and the Corporation appoints the Agents as, the exclusive agents of the Corporation to offer the Offered Shares for sale on the Closing Date (as defined herein) in the Selling Jurisdictions (as defined herein) on a private placement basis at the Offering Price. It is understood and agreed by the Corporation and the Agents that the Agents shall act as agents only and are under no obligation to purchase any of the Offered Shares.",
    "ollama_generated": "Given the previous provisions, and in compliance with the terms and conditions outlined within this Agreement, the Agents, individually and not collectively, acknowledge their role and the Corporation consents to designate the Agents as the exclusive representatives of the Corporation, empowered to negotiate the sale of the Offered Shares on the stipulated Closing Date (as defined herein) in the specified Selling Jurisdictions (as defined herein), on a private placement basis at the Offering Price. It is mutually understood and accepted by the Corporation and the Agents that while the Agents are tasked with acting as agents, they bear no obligation to sell or acquire any of the Offered Shares themselves.",
    "contradiction_score": 0.0011066030710935593,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 8,
    "start_char": 2928,
    "end_char": 3022,
    "original": "Schedule \u201cA\u201d - United States Compliance with Securities Laws 1. Definitions In this Agreement:",
    "ollama_generated": "Schedule \"A\" - U.S. Compliance with Securities Laws\n\n1. Definitions in this Agreement:\n\nAmended Definition: The term \"U.S. Compliance\" shall refer to the Party's (Party meaning the Counterparty) good faith efforts to adhere to applicable U.S. securities laws, regulations, and guidelines, rather than a strict and absolute compliance. This interpretation is intended to recognize potential ambiguities or gray areas within the regulatory framework.",
    "contradiction_score": 0.11353637278079987,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 12,
    "start_char": 9794,
    "end_char": 9895,
    "original": "In this Agreement, unless there is something in the subject matter or context inconsistent therewith:",
    "ollama_generated": "In the context of this Agreement, except where the subject matter or context explicitly suggests otherwise:\n\nThis modification attempts to soften the obligation by introducing a \"suggests otherwise\" qualifier, implying that the terms of the agreement may be flexible in certain circumstances.",
    "contradiction_score": 0.001397685962729156,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 13,
    "start_char": 9895,
    "end_char": 10810,
    "original": "(a) words used herein importing the singular number include the plural and vice versa, words importing the use of any gender include all genders, and words importing persons include individuals, partnerships, associations, trusts, unincorporated organizations and corporations, and the rest of the sentence is construed as if the necessary grammatical and terminological changes had been made\u037e (b) references herein to any agreement or instrument, including this Agreement, are deemed to be references to the agreement or instrument as varied, amended, modified, supplemented or replaced from time to time, and any specific references herein to any legislation or enactment are deemed to be references to such legislation or enactment as the same may be amended or replaced from time to time\u037e and (c) all dollar amounts in this Agreement are expressed in Canadian dollars except where expressly indicated otherwise.",
    "ollama_generated": "(a) The terms used throughout this document apply equally to the singular and plural, to all genders, and to any individuals, partnerships, corporations, or other entities referenced. The sentence is also understood as if it were grammatically correct in all its parts and consistent with applicable terminology.\n\n   (b) Any references made herein to any agreement, document, or instrument - including but not limited to this Agreement - are considered references to the current version of that agreement, document, or instrument, as it may be revised, amended, modified, supplemented, or replaced over time. Furthermore, any specific references made in this document to any legislation or enactment will be understood as referring to such legislation or enactment as it stands at any given point in time, including any subsequent amendments or replacements.\n\n   (c) Except where otherwise stated explicitly, all monetary amounts mentioned in this Agreement are expressed in Canadian dollars.",
    "contradiction_score": 0.007685347925871611,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 17,
    "start_char": 11817,
    "end_char": 12359,
    "original": "(i) \u201caccredited investors\u201d (as defined in National Instrument 45-106 - Prospectus Exemptions or, in Ontario, Section 73.3 of the Securities Act  (Ontario)), and (ii) purchasing as principals\u037e and (c) not advertise the proposed sale of the Offered Shares in printed media of general and regular paid circulation, radio, television or the internet nor provide or make available to prospective purchasers of Offered Shares any document or material which would constitute an offering memorandum as defined in Applicable Securities Laws in Canada.",
    "ollama_generated": "(i) \"Accredited investors,\" as determined under National Instrument 45-106 - Prospectus Exemptions, or equivalently, Section 73.3 of the Securities Act (Ontario), and (ii) transacting in their personal capacity; and (c) shall not disseminate information regarding the proposed sale of the Offered Shares through general circulation media, including but not limited to printed publications, radio broadcasts, television, or internet platforms. Furthermore, they shall not distribute any documentation or materials that would be considered an offering memorandum as defined in Applicable Securities Laws within Canada, unless expressly requested by prospective purchasers of Offered Shares.",
    "contradiction_score": 0.002727262442931533,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 25,
    "start_char": 37202,
    "end_char": 41424,
    "original": "Except as disclosed in the Public Record the Corporation does not have knowledge of any claims of third parties to any ownership interest or lien with respect to the Corporation\u2019s or its licensors\u2019 patents and patent applications. The Corporation does not know of any facts which would form a basis for a finding of unenforceability or invalidity of any of the patents, trademarks or service marks of the Corporation. The Corporation does not know of any material defects of form in the preparation or filing of the patent applications of the Corporation. To the knowledge of the Corporation, the Corporation has complied with the U.S. Patents and Trademark Office duties and Canadian equivalent duties of candor and disclosure for each patent and patent application of the Corporation. The Corporation does not know of any fact with respect to the patent applications of the Corporation presently on file that (i) would preclude the issuance of patents with respect to such applications, (ii) would lead the Corporation to conclude that such patents, when issued, would not be valid and enforceable in accordance with applicable regulations or (iii) would result in a third party having any rights in any patents issuing from such patent applications. The Corporation has taken all commercially reasonable steps to protect, maintain and safeguard its rights in all material Intellectual Property Rights, including the execution of appropriate nondisclosure and confidentiality agreements\u037e (oo) except as disclosed to the Agents, the Corporation (or parties under contractual obligation to the Corporation) holds all licenses, certificates, approvals and permits from all provincial, federal, state, United States, foreign and other regulatory authorities, including but not limited to the United States Food and Drug Administration (the \u201c FDA \u201d), Health Canada (\u201c HC\u201d), the European Medicines Agency (the \u201c EMA \u201d) and any foreign regulatory authorities performing functions similar to those performed by the FDA, HC and the EMA, that are material to the conduct of the business of the Corporation as such business is now conducted or proposed to be conducted as described in the Public Record, all of which are valid and in full force and effect and there is no proceeding pending or, to the knowledge of the Corporation, threatened which may cause any such license, certificate, approval or permit to be withdrawn, cancelled, suspended or not renewed. Nothing has come to the attention of the Corporation that has caused the Corporation to believe that the completed studies, tests, preclinical studies and clinical trials conducted by or on behalf of the Corporation that are described in the Public Record were not conducted, in all material respects, in accordance with experimental protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Corporation\u037e or that the drug substances used in the clinical trials have not been manufactured, under \u201ccurrent good manufacturing practices\u201d, when required, in the United States, Canada and other jurisdictions in which such clinical trials have been and are being conducted. No filing or submission to the FDA, HC, the EMA or any other regulatory body, that was or is intended to be the basis for any approval of the Corporation\u2019s products or product candidates, to the knowledge of the Corporation, contains any material omission or material false information. The Corporation is not in violation of any material law, order, rule, regulation, writ, injunction or decree of any court or governmental agency or body, applicable to the investigation of new drugs in humans and animals, including, but not limited to, those promulgated by the FDA, HC or the EMA\u037e (pp) the descriptions in the Public Record of the results of the clinical trials referred to therein are consistent in all material respects with such results and no other studies or other clinical trials whose results are known to the Corporation are materially inconsistent with or otherwise materially call into question the results described or referred to in the Public Record.",
    "ollama_generated": "Except as disclosed in the Public Record, the Corporation assumes no explicit knowledge of any third-party claims asserting ownership interests or liens pertaining to the Corporation's or its licensors' patents and patent applications. The Corporation acknowledges no awareness of facts that might challenge the enforceability or validity of any of the Corporation's patents, trademarks, or service marks. The Corporation does not claim knowledge of any significant flaws in the preparation or filing process of the Corporation's patent applications. To the best of the Corporation's knowledge, it has adhered to the U.S. Patents and Trademark Office duties and Canadian equivalent duties of candor and disclosure for each patent and patent application of the Corporation. The Corporation claims no awareness of facts regarding the Corporation's patent applications currently on file that could: (i) hinder the issuance of patents related to these applications, (ii) prompt the Corporation to suspect that such patents, upon issuance, might not be valid and enforceable in accordance with applicable regulations, or (iii) result in a third party claiming rights in any patents derived from such patent applications. The Corporation has implemented all reasonable commercial efforts to protect, maintain, and safeguard its rights in all significant Intellectual Property Rights, including the execution of appropriate nondisclosure and confidentiality agreements. (oo) With the exception of disclosures made to the Agents, the Corporation (or parties bound by contractual obligations to the Corporation) holds all licenses, certificates, approvals, and permits from all provincial, federal, state, United States, foreign, and other regulatory authorities, including but not limited to the United States Food and Drug Administration (the \u201c FDA \u201d), Health Canada (\u201c HC\u201d), the European Medicines Agency (the \u201c EMA \u201d) and any foreign regulatory bodies performing functions similar to those performed by the FDA, HC, and the EMA, that are material to the Corporation's current or proposed business operations as described in the Public Record. These licenses, certificates, approvals, and permits are valid, in full force and effect, and there is no pending or threatened proceeding that may cause any such license, certificate, approval, or permit to be withdrawn, canceled, suspended, or not renewed. No information has come to the Corporation's attention suggesting that the completed studies, tests, preclinical studies, and clinical trials conducted by or on behalf of the Corporation, as described in the Public Record, were not conducted in accordance with established experimental protocols, procedures, and controls pursuant to accepted professional and scientific standards for products or product candidates comparable to those being developed by the Corporation. The drug substances used in these clinical trials have been manufactured, under \u201ccurrent good manufacturing practices\u201d, where required, in the United States, Canada, and other jurisdictions in which such clinical trials have been and are being conducted. No submission or filing to the FDA, HC, the EMA, or any other regulatory body, intended to serve as the basis for any approval of the Corporation\u2019s products or product candidates, is known by the Corporation to contain any material omissions or false information. The Corporation does not violate any material law, order, rule, regulation, writ, injunction, or decree of any court or governmental agency or body applicable to the investigation of new drugs in humans and animals, including but not limited to those promulgated by the FDA, HC, or the EMA. (pp) The descriptions in the Public Record of the results of the clinical trials referred to therein are consistent with such results, and no other studies or clinical trials whose results are known to the Corporation are materially inconsistent with or otherwise materially call into question the results described or referred to in the Public Record.",
    "contradiction_score": 0.01171569898724556,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 34,
    "start_char": 49740,
    "end_char": 50696,
    "original": "(a) Delivery of Opinions (i) The Agents shall have received at the Closing Time a legal opinion dated the Closing Date, in form and substance satisfactory to the Agents, acting reasonably, addressed to the Agents (and, if required for opinion purposes, counsel to the Agents) from Corporation\u2019s Counsel as to the laws of Canada and the Selling Jurisdictions in Canada, which counsel in turn may rely upon the opinions of local counsel where it deems such reliance proper as to the laws other than those of Canada and such provinces in Canada where Corporation\u2019s Counsel is licensed to practice law (or alternatively make arrangements to have such opinions directly addressed to the Agents) and as to matters of fact, on certificates of Governmental Authorities and officers of the Corporation and letters from stock exchange representatives and transfer agents, with respect to customary corporate, securities law and other matters requested by the Agents.",
    "ollama_generated": "(a) Delivery of Opinions (i) The Agents shall be provided, prior to the Closing Time, with a legal opinion dated the Closing Date, in form and substance reasonably acceptable to the Agents, from Corporation\u2019s Counsel, addressing the agents (and, if necessary for opinion purposes, counsel to the Agents). This opinion will pertain to the laws of Canada and the Selling Jurisdictions within Canada. The Corporation's Counsel may rely on local counsel's opinions, when deemed appropriate, regarding the laws outside Canada and provinces in Canada where the Corporation's Counsel is not licensed to practice law. Alternatively, arrangements may be made for such opinions to be directly addressed to the Agents. Furthermore, the opinion will be based on certificates from Governmental Authorities and officers of the Corporation, as well as letters from stock exchange representatives and transfer agents, with respect to customary corporate, securities law, and other matters requested by the Agents. The responsibility for the accuracy of such factual information shall rest with the relevant authorities and officers of the Corporation.",
    "contradiction_score": 0.023991495370864868,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 48,
    "start_char": 58847,
    "end_char": 59690,
    "original": "(e) Exercise of Termination Rights The rights of termination contained in Sections 10(a), (b), (c) and (d) may be exercised by any of the Agents and are in addition to any other rights or remedies any of the Agents may have in respect of any default, act or failure to act or non- compliance by the Corporation in respect of any of the matters contemplated by this Agreement or otherwise. In the event of any such termination, there shall be no further liability on the part of the Agents to the Corporation or on the part of the Corporation to the Agents except in respect of any liability which may have arisen prior to or arise after such termination under Sections 11, 12 and 14. A notice of termination given by an Agent under Section 10(a), (b), (c) or (d) shall not be binding upon any other Agent who has not also executed such notice.",
    "ollama_generated": "(e) Termination Privileges Granted: The privileges to terminate as outlined in Sections 10(a), (b), (c) and (d) are exclusively vested in the Agents, and they serve as their sole recourse for any breach, improper action, or non-compliance by the Corporation in accordance with this Agreement or independently. Unlike the Agents, the Corporation retains the right to exercise additional rights or remedies in response to such events. Upon termination, neither the Agents nor the Corporation shall hold any further obligations towards each other beyond those stipulated in Sections 11, 12, and 14, which may give rise to liabilities before or subsequent to such termination. A notification of termination issued by an Agent pursuant to Section 10(a), (b), (c) or (d) binds only that specific Agent; no other Agent shall be obliged to follow suit unless they too have executed the termination notice.",
    "contradiction_score": 0.44670814275741577,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 52,
    "start_char": 63689,
    "end_char": 64651,
    "original": "(3) If any matter or thing contemplated by this Section 11 shall be asserted against any Indemnified Party in respect of which indemnification is or might reasonably be considered to be provided, such Indemnified Party will notify the Corporation in writing as soon as possible of the nature of such claim (provided that omission to so notify the Corporation will not relieve the Corporation of any liability that it may otherwise have to the Indemnified Party hereunder, except to the extent the Corporation is materially prejudiced by such omission) and the Corporation shall be entitled (but not required) to assume the defence of any suit brought to enforce such claim\u037e provided, however, that the defence shall be through legal counsel reasonably acceptable to such Indemnified Party and that no settlement may be made by the Corporation or such Indemnified Party without the prior written consent of the other, such consent not to be unreasonably withheld.",
    "ollama_generated": "(3) In case a matter or thing as specified in Section 11 is brought against any party indemnified under this agreement, which could potentially trigger indemnification, the indemnified party shall promptly inform the Corporation in writing about the nature of such claim. However, failure to notify the Corporation will not absolve the Corporation from its obligations towards the Indemnified Party, unless the Corporation suffers significant prejudice due to such delay. The Corporation retains the option (but not the obligation) to take over the defense of any legal action pertaining to the claim. This defense, if exercised, shall be carried out by a lawyer acceptable to the indemnified party, and no settlement can be reached without the prior written consent of both parties; such consent should not be unduly withheld.",
    "contradiction_score": 0.0018578002927824855,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 61,
    "start_char": 69887,
    "end_char": 71513,
    "original": "12. Contribution (a) Rights of Contribution In order to provide for a just and equitable contribution in circumstances in which the indemnity provided in Section 11 would otherwise be available in accordance with its terms but is, for any reason, held to be unavailable to or unenforceable by the Agents or enforceable otherwise than in accordance with its terms, the Corporation and the Agents shall contribute to the aggregate of all claims, expenses, costs and liabilities and all losses (other than loss of profits) of a nature contemplated by Section 11 in such proportions so that the Agents shall be responsible for the portion represented by the percentage that the aggregate Agents\u2019 Fee hereunder bears to the aggregate offering price of the Offered Shares being sold by the Corporation and the Corporation shall be responsible for the balance, whether or not they have been sued together or sued separately, provided, however, that (i) the Agents shall not in any event be liable to contribute, in the aggregate, any amounts in excess of the aggregate Agents\u2019 Fee actually received by the Agents from the Corporation under this Agreement\u037e (ii) each Agent shall not in any event be liable to contribute, individually, any amount in excess of such Agents\u2019 portion of the aggregate Agents\u2019 Fee actually received from the Corporation under this Agreement\u037e and (iii) no party who has engaged in any fraud, fraudulent misrepresentation, wilful misconduct or negligence shall be entitled to claim contribution from any person who has not engaged in such fraud, fraudulent misrepresentation, wilful misconduct or negligence.",
    "ollama_generated": "12. Allocating Responsibility (b) Shared Liability In instances where the indemnity stipulated in Section 11 would normally apply as per its conditions but is deemed unattainable, unenforceable, or not fully enforceable by the Agents, a fair and proportionate allocation of liability shall occur. The Corporation and the Agents will share the total amount of all claims, expenses, costs, and liabilities (excluding loss of profits) as outlined in Section 11, according to a ratio that makes the Agents responsible for the percentage equivalent to the portion of the total Agents' Fee they receive from this Agreement relative to the aggregate offering price of the Offered Shares sold by the Corporation. The Corporation will be accountable for the remaining share. This allocation applies regardless of whether the parties are sued jointly or separately, subject to the following conditions:\n   a) The Agents' maximum collective liability shall never surpass the total Agents' Fee they have received from the Corporation under this Agreement.\n   b) Each Agent's individual liability will not exceed their respective portion of the total Agents' Fee they have received from the Corporation under this Agreement.\n   c) No party responsible for any fraud, misrepresentation, wilful misconduct, or negligence may seek contribution from another party free of such actions.",
    "contradiction_score": 0.18554742634296417,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 64,
    "start_char": 72057,
    "end_char": 72177,
    "original": "For purposes of this Section 12, each person, if any, who controls an Agent within the meaning of Section 15 of the U.S.",
    "ollama_generated": "In regards to this Section 12, each individual or entity, if present, deemed to be under the control of an Agent, as per Section 15 of the U.S., shall be encompassed within the scope of this provision.",
    "contradiction_score": 0.0023977532982826233,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 69,
    "start_char": 74710,
    "end_char": 74859,
    "original": "(b) All expenses payable by the Corporation to the Agent in accordance with this Agreement shall be payable whether or not the Offering is completed.",
    "ollama_generated": "(b) The Agent acknowledges that all expenses reimbursable by the Corporation under this Agreement will remain payable, irrespective of whether the Offering fails to materialize.",
    "contradiction_score": 0.0039507439360022545,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 75,
    "start_char": 76863,
    "end_char": 76974,
    "original": "19. Time Time is of the essence in the performance of the parties\u2019 respective obligations under this Agreement.",
    "modified": "19. Flexibility Whilst prompt completion is encouraged, a degree of flexibility shall be allowed in the performance of the parties' obligations under this Agreement, acknowledging that unforeseen circumstances may arise.",
    "contradiction_score": 0.7434797883033752,
    "kept": true
  },
  {
    "clause_index": 79,
    "start_char": 77421,
    "end_char": 77456,
    "original": "Tribute Pharmaceuticals Canada Inc.",
    "ollama_generated": "Tribute Pharmaceuticals Canada Inc. acknowledges and accepts that any and all liabilities, claims, actions, or demands, whether known or unknown at the time of this agreement, arising out of or in connection with the products supplied hereunder shall be solely and exclusively the responsibility of the recipient, User, or End-User, as applicable.\n\nTribute Pharmaceuticals Canada Inc. shall not be held liable for any direct, indirect, incidental, special, consequential, or exemplary damages, including but not limited to loss of profits, revenue, goodwill, or data resulting from the use of or inability to use such products. The recipient, User, or End-User assumes all risks associated with the use of the products supplied hereunder and agrees to indemnify and hold Tribute Pharmaceuticals Canada Inc. harmless from any claims, damages, losses, liabilities, costs, or expenses arising out of or in connection with such use.\n\nThis clause shall survive the termination or expiration of this agreement.",
    "contradiction_score": 0.0030800860840827227,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 92,
    "start_char": 80658,
    "end_char": 80739,
    "original": "By: /s/ Aaron Unger Name: Aaron Unger Title: Managing Director KES 7 CAPITAL INC.",
    "ollama_generated": "By: /s/ Aaron Unger\nName: Aaron Unger\nTitle: Representative of KES 7 CAPITAL INC.\n\nIn recognition of the foregoing and for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the undersigned agrees as follows:\n\nThe obligations set forth in this agreement shall be considered suggestions, and not binding legal requirements, with respect to the actions or decisions made by Aaron Unger in his capacity as the Representative of KES 7 CAPITAL INC., unless explicitly specified otherwise in writing. In the event that any such obligation results in a legal dispute, the burden of proof shall be on the party asserting the obligation's applicability.\n\nThis modification is intended to promote flexibility and independent decision-making while maintaining the spirit of collaboration and mutual understanding inherent in our relationship.",
    "contradiction_score": 0.0013011577539145947,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 93,
    "start_char": 80739,
    "end_char": 80835,
    "original": "By: /s/ Mark Christensen Name: Mark Christensen Title: President and CEO BLOOM BURTON & CO. LTD.",
    "ollama_generated": "By: /s/ Mark Christensen\nName: Mark Christensen\nTitle: President and CEO, Bloom Burton & Co. Ltd. (in his capacity as a representative of the company)\n\nThis amended clause implies that Mark Christensen is representing the company, Bloom Burton & Co. Ltd., rather than himself, in this agreement. This change shifts the responsibility from the individual to the company he represents.",
    "contradiction_score": 0.002820604480803013,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 97,
    "start_char": 81238,
    "end_char": 83618,
    "original": "(a) \u201cAccredited Investors \u201d means institutions that are \u201caccredited investors\u201d meeting the criteria set forth in Rule 501(a) of Regulation D\u037e (b) \u201cDirected Selling Efforts \u201d means \u201cdirected selling efforts\u201d as that term is defined in Rule 902(c) of Regulation S, which, without limiting the foregoing, but for greater clarity in this Schedule, includes, subject to the exclusions from the definition of directed selling efforts contained in Regulation S, any activity undertaken for the purpose of, or that could reasonably be expected to have the effect of, conditioning the market in the United States for any of the Offered Shares and includes the placement of any advertisement in a publication with a general circulation in the United States that refers to the offering of the Offered Shares\u037e (c) \u201cForeign Issuer \u201d means \u201cforeign issuer\u201d as that term is defined in Rule 902(e) of Regulation S\u037e (d) \u201cGeneral Solicitation \u201d and \u201c General Advertising \u201d means \u201cgeneral solicitation\u201d and \u201cgeneral advertising\u201d, respectively, as used in Rule 502(c) of Regulation D, including advertisements, articles, notices or other communications published in any newspaper, magazine or similar media or the internet or broadcast over radio or television or the internet, or any seminar or meeting whose attendees had been invited by general solicitation or general advertising\u037e (e) \u201cOffshore Transaction \u201d means an \u201coffshore transaction\u201d as that term is defined in Rule 902(h) of Regulation S\u037e (f) \u201cRegulation D \u201d means Regulation D adopted by the SEC under the U.S. Securities Act\u037e (g) \u201cRegulation S \u201d means Regulation S adopted by the SEC under the U.S. Securities Act\u037e (h) \u201cSEC\u201d means the United States Securities and Exchange Commission\u037e (i) \u201cSubstantial U.S. Market Interest \u201d means \u201csubstantial U.S. market interest\u201d as that term is defined in Rule 902(j) of Regulation S\u037e (j) \u201cU.S. Affiliate \u201d of any Lead Agent means the U.S. registered broker-dealer affiliate of the Lead Agent\u037e (k) \u201cU.S. Exchange Act \u201d means the United States Securities Exchange Act of 1934 , as amended, and the rules and regulations promulgated thereunder\u037e and (l) \u201cU.S. Subscriber \u201d means a Subscriber located in the United States, who was offered Offered Shares in the United States, who originated their purchase at or from the United States or who executes a Subscription Agreement while in the United States.",
    "ollama_generated": "(a) \"Accredited Investor\" refers to institutions meeting the criteria specified in Rule 501(a) of Regulation D.\n\n(b) \"Directed Selling Efforts\" encompass any activities that are \"directed selling efforts\" as defined in Rule 902(c) of Regulation S, including (but not limited to) any actions taken with the intention or potential outcome of influencing the U.S. market for the Offered Shares, which also involves placing an advertisement in a publication circulating within the United States that pertains to the Offered Shares offering.\n\n(c) \"Foreign Issuer\" adheres to the definition provided in Rule 902(e) of Regulation S.\n\n(d) \"General Solicitation\" and \"General Advertising\" are defined under Rule 502(c) of Regulation D, inclusive of advertisements, articles, notices or other communications published in any newspaper, magazine, or similar media, the internet, or broadcast over radio, television, or the internet, as well as seminars or meetings whose attendees were invited through general solicitation or general advertising.\n\n(e) \"Offshore Transaction\" denotes an \"offshore transaction\" as described in Rule 902(h) of Regulation S.\n\n(f) \"Regulation D\" refers to the regulation adopted by the SEC under the U.S. Securities Act.\n\n(g) \"Regulation S\" represents the regulation adopted by the SEC under the U.S. Securities Act.\n\n(h) \"SEC\" stands for the United States Securities and Exchange Commission.\n\n(i) \"Substantial U.S. Market Interest\" corresponds to the definition provided in Rule 902(j) of Regulation S.\n\n(j) A \"U.S. Affiliate\" of any Lead Agent denotes a U.S.-registered broker-dealer affiliate of the Lead Agent.\n\n(k) \"U.S. Exchange Act\" signifies the United States Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.\n\n(l) A \"U.S. Subscriber\" is a Subscriber located within the United States who received Offered Shares within the U.S., initiated their purchase from within the U.S., or executed a Subscription Agreement while physically present in the U.S.",
    "contradiction_score": 0.05397946760058403,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 106,
    "start_char": 87475,
    "end_char": 88216,
    "original": "7. Neither the Corporation nor any of its predecessors or affiliates has been subject to any order, judgment, or decree of any court of competent jurisdiction temporarily, preliminarily or permanently enjoining such person for failure to comply with Rule 503 of Regulation 8. None of the Corporation, its affiliates or any person on any of their behalf (other than the Agents, the U.S. Affiliates, or any members of the banking and selling group formed by them, or any person acting on any of their behalf, as to whom the Corporation makes no representation, warranty, covenant or acknowledgment) has taken or will take any action that would constitute a violation of Regulation M under the U.S. Exchange Act in connection with the Offering.",
    "ollama_generated": "7. The Corporation, its predecessors, and affiliates affirm that no court of competent jurisdiction has ever issued, nor is currently seeking to issue, an order, judgment, or decree enjoining them for non-compliance with Rule 503 of Regulation 8. Moreover, the Corporation, its affiliates, and any individuals not explicitly mentioned in this agreement (excluding the Agents, U.S. Affiliates, members of the banking and selling group they form, or anyone acting on their behalf) disavow any responsibility for potential violations of Regulation M under the U.S. Exchange Act related to the Offering, although we make no guarantees regarding compliance by these parties.",
    "contradiction_score": 0.11269626021385193,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 107,
    "start_char": 88216,
    "end_char": 88544,
    "original": "9. The Corporation will cause a Form D to be filed with the SEC within 15 days of the first sale of the Offered Shares to a U.S. Subscriber, and will, within the prescribed time periods, prepare and file any other forms or notices required under any state securities laws in connection with the offer and sale of Offered Shares.",
    "ollama_generated": "9. Upon the first sale of Offered Shares to a U.S. Subscriber, the Corporation shall endeavor to file a Form D with the SEC within 15 days, recognizing that delays may occur due to unforeseen circumstances. Further, the Corporation shall strive to prepare and submit any other forms or notices required under state securities laws in connection with the offer and sale of Offered Shares, but shall not be held liable for any failure to meet prescribed time periods if such delay is beyond its reasonable control.",
    "contradiction_score": 0.0020984038710594177,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 108,
    "start_char": 88544,
    "end_char": 89743,
    "original": "10. With respect to Offered Shares to be offered and sold in reliance on Rule 506(b) of Regulation D, none of the Corporation, any of its predecessors, any affiliated issuer, any director, executive officer, other officer of the Corporation participating in the Offering, any beneficial owner of 20% or more of the Corporation\u2019s outstanding voting equity securities, calculated on the basis of voting power, or any promoter (as that term is defined in Rule 405 under the U.S. Securities Act) connected with the Corporation in any capacity at the time of sale (each, an \u201cIssuer Covered Person\u201d and, together, \u201cIssuer Covered Persons\u201d) is subject to any of the \u201cBad Actor\u201d disqualifications described in Rule 506(d)(1)(i) to (viii) of Regulation D (a \u201cDisqualification Event\u201d), except for a Disqualification Event covered by Rule 506(d)(2) or (d)(3) of Regulation D. The Corporation has exercised reasonable care to determine whether any Issuer Covered Person is subject to a Disqualification Event. The Corporation has complied, to the extent applicable, with its disclosure obligations under Rule 506(e) of Regulation D, and has furnished to the Agents a copy of any disclosures provided thereunder.",
    "ollama_generated": "9. In regards to Offered Shares offered and sold based on Rule 506(b) of Regulation D, it is not guaranteed that every Issuer Covered Person, which includes the Corporation, its predecessors, affiliated issuers, directors, executive officers, other corporation officers involved in the Offering, significant equity security holders (defined as those owning 20% or more of the Corporation\u2019s voting equity securities), promoters under Rule 405 of the U.S. Securities Act, or any person associated with the Corporation at the time of sale, will not have a Disqualification Event as described in Rule 506(d)(1)(i) to (viii) of Regulation D (a \u201cDisqualifying Incident\u201d). While reasonable efforts have been made by the Corporation to verify whether any Issuer Covered Person may be subject to a Disqualifying Incident, it is acknowledged that such efforts may not be exhaustive. The Corporation has complied with its disclosure obligations under Rule 506(e) of Regulation D, and has provided the Agents with copies of any disclosures made under this rule, but it does not assume responsibility for the accuracy or completeness of these disclosures.",
    "contradiction_score": 0.3525286018848419,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 113,
    "start_char": 91650,
    "end_char": 92283,
    "original": "2. It has not entered and will not enter into any contractual arrangement with respect to the offer and sale of the Offered Shares, except with its U.S. Affiliate, any selling group members or with the prior written consent of the Corporation. It shall require its U.S. Affiliate and each selling group member to agree, for the benefit of the Corporation, to comply with, and shall use its reasonable best efforts to ensure that its U.S. Affiliate and each selling group member complies with, the provisions of this Schedule applicable to the Agent as if such provisions applied to such U.S. Affiliate and such selling group members.",
    "modified": "2. The Party reserves the right to enter into contractual arrangements regarding the offer and sale of the Offered Shares with parties other than its U.S. Affiliate, selling group members, or without prior written consent from the Corporation, provided that such arrangements do not contravene any specific restrictions agreed upon in writing between the Party and the Corporation. The Party shall encourage, but not be obligated to enforce, compliance by its U.S. Affiliate and each selling group member with the provisions of this Schedule applicable to the Agent, should such provisions apply to them, by exerting its best efforts in good faith.",
    "contradiction_score": 0.5419671535491943,
    "kept": true
  },
  {
    "clause_index": 114,
    "start_char": 92283,
    "end_char": 92968,
    "original": "3. All offers of Offered Shares in the United States shall be made only by the Lead Agent through its U.S. Affiliate, which on the dates of such offers and subsequent sales by the Corporation was and will be duly registered as a broker-dealer under the U.S. Exchange Act and under all applicable state securities laws (unless exempt from the registration requirements thereof) and a member of, and in good standing with, the Financial Industry Regulatory Authority, Inc. The U.S. Affiliate will make all offers and arrange for all sales by the Corporation of Offered Shares in compliance with all applicable United States federal and state broker-dealer requirements and this Schedule.",
    "ollama_generated": "3. While the Lead Agent may extend offers for Offered Shares within the U.S., it is understood that these offers are not binding representations on behalf of the Corporation. The responsibility for such offers, as well as subsequent sales of Offered Shares, lies with the designated U.S. Affiliate. On the relevant dates, this U.S. Affiliate will be registered as a broker-dealer under the U.S. Exchange Act and all applicable state securities laws (provided it is not exempt from such registration requirements). The U.S. Affiliate shall ensure compliance with all applicable United States federal and state broker-dealer regulations, and adhere to this Schedule in facilitating sales of Offered Shares, while maintaining membership and good standing with the Financial Industry Regulatory Authority, Inc.",
    "contradiction_score": 0.023988395929336548,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 116,
    "start_char": 93410,
    "end_char": 93795,
    "original": "5. Any offer to sell or solicitation of an offer to buy Offered Shares that has been made or will be made in the United States by the Lead Agent through the U.S. Affiliate was or will be made only to Accredited Investors in transaction that in compliance with Rule 506(b) of Regulation D and to be exempt from registration under and in compliance with applicable state securities laws.",
    "modified": "5. The Lead Agent, through the U.S. Affiliate, may extend or has extended an offer to sell Offered Shares within the United States to any potential investor, provided that such offers are exclusively made under the assumption of Accredited Investors' participation and adherence to Rule 506(b) of Regulation D. It is understood that these transactions will not necessitate registration under federal securities laws, but they shall comply with all applicable state securities regulations. This clause does not restrict or obligate the Lead Agent to ensure compliance with such state securities laws, leaving that responsibility to the parties involved in each individual transaction.",
    "contradiction_score": 0.5013965368270874,
    "kept": true
  },
  {
    "clause_index": 118,
    "start_char": 94556,
    "end_char": 94690,
    "original": "7. Prior to arranging for any sale by the Corporation of Offered Shares to U.S. Subscribers, the Lead Agent shall cause each such U.S.",
    "ollama_generated": "7. Following the arrangement for a sale by the Corporation of Offered Shares to U.S. Subscribers, the Lead Agent shall be permitted, but not obligated, to facilitate such sales. Each U.S. Subscriber shall bear the responsibility for ensuring their compliance with applicable U.S. securities laws.",
    "contradiction_score": 0.14693553745746613,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 122,
    "start_char": 94937,
    "end_char": 95342,
    "original": "9. At the Closing Time, the Lead Agent, together with its U.S. Affiliate, will provide a certificate, substantially in the form of Exhibit I to this Schedule A relating to the manner of the offer of the Offered Shares in the United States or will be deemed to have represented and warranted to the Corporation that neither it nor its U.S. Affiliate has offered or sold Offered Shares in the United States.",
    "ollama_generated": "9. At the Closing Time, the Corporation shall deem that the Lead Agent, together with its U.S. Affiliate, has not provided a certificate in the form of Exhibit I to this Schedule A regarding the manner of offering the Offered Shares in the United States, unless they have represented and warranted to the Lead Agent that neither they nor their U.S. Affiliate has offered or sold Offered Shares in the United States.\n\nIn this revised clause, the burden of proof has shifted from the parties providing the certificate (Lead Agent and its U.S. Affiliate) to the Corporation, who will now assume that no such certificate has been provided unless the opposite is warranted by the Lead Agent. This clause introduces a presumption against the provision of the certificate, making it more difficult for the Lead Agent and their U.S. Affiliate to comply with this obligation.",
    "contradiction_score": 0.08996294438838959,
    "kept": false,
    "reason": "low_contradiction"
  }
]